An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
This report contains market size and forecasts of Infantile Spasm Treatment in Global, including the following market information:
Global Infantile Spasm Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Infantile Spasm Treatment market was valued at 144 million in 2021 and is projected to reach US$ 182.6 million by 2028, at a CAGR of 3.4% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Infantile Spasm Treatment include Mallinckrodt, H. Lundbeck, Insys Therapeutics, Orphelia Pharma, Valerion Therapeutics, Catalyst Pharmaceuticals, Anavex Life Sciences, Retrophin and GW Pharmaceuticals. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Infantile Spasm Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Infantile Spasm Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Infantile Spasm Treatment Market Segment Percentages, by Type, 2021 (%)
Oral
Parenteral
Global Infantile Spasm Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Infantile Spasm Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Other
Global Infantile Spasm Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Infantile Spasm Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Infantile Spasm Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Infantile Spasm Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Mallinckrodt
H. Lundbeck
Insys Therapeutics
Orphelia Pharma
Valerion Therapeutics
Catalyst Pharmaceuticals
Anavex Life Sciences
Retrophin
GW Pharmaceuticals